Amprion and Prema Cognition have partnered to integrate Prema Cognition’s PREMAZ digital cognitive assessment with Amprion’s seed amplification biomarker assays, creating a streamlined pathway for detecting early signs of neurodegenerative diseases. The collaboration links remote or clinic-based memory screening with laboratory confirmation of pathological biomarkers, aiming to improve early detection accuracy. Announced recently, the initiative targets conditions like Alzheimer’s disease by combining cognitive performance data with biological evidence of protein misfolding.
PREMAZ is a 10- to 15-minute digital test designed to evaluate precision memory function through interactive tasks administered via tablet or computer. It captures subtle cognitive changes that may precede clinical diagnosis by years. Amprion’s seed amplification assay detects misfolded proteins such as amyloid-beta and tau in cerebrospinal fluid or blood, offering a biological readout of neurodegenerative processes. Together, the tools form a two-step assessment: initial screening with PREMAZ followed by biomarker testing for those showing cognitive anomalies.
By using PREMAZ as a first-line tool, healthcare providers can identify individuals who warrant further biomarker investigation, reducing unnecessary testing and focusing resources on high-risk cases. Prema Cognition emphasizes that the test is designed for use in diverse settings, including primary care clinics and remote monitoring programs. Amprion notes that its assay has demonstrated high sensitivity in detecting early pathological changes, even before significant cognitive decline becomes apparent. The integration allows for longitudinal tracking, where changes in PREMAZ scores over time can correlate with biomarker trends, supporting personalized monitoring strategies.
One challenge involves ensuring equitable access to both digital testing and biomarker assays across different healthcare systems and socioeconomic groups. Technical literacy and internet connectivity could affect PREMAZ usability in certain populations, while biomarker testing requires specialized lab infrastructure. Data privacy and secure transmission of cognitive and biological information also need robust safeguards. Both companies state they are working with clinical partners to validate the pathway in real-world environments and address usability barriers through simplified interfaces and community outreach programs.
What is the primary goal of combining PREMAZ with Amprion’s biomarker assay? The goal is to create a more accurate early detection pathway by linking cognitive screening with biological confirmation, enabling earlier intervention in neurodegenerative diseases.
How long does the PREMAZ assessment take to complete? PREMAZ is designed to be completed in 10 to 15 minutes, making it suitable for routine clinical visits or remote monitoring without significant time burden.
Is the biomarker test invasive or painful? Amprion’s seed amplification assay typically uses cerebrospinal fluid or blood samples, which involve standard clinical procedures such as lumbar puncture or venipuncture, depending on the sample type required.